Drug Security Forum

Responses to the COVID-19 pandemic must be based on solidarity and cooperation among countries, societies, and industries. The pharma industry has come to stand at the centre of a large-scale transformation of global economies and healthcare. Companies all over the world have turned their resources to developing a vaccine against the new virus, while continuing to respond to the growing needs of the healthcare system and patients. The expansion of production capacity has become one of the first steps taken by pharmaceutical manufacturers in response to the challenges of the pandemic. Taking into account the new environment, the innovative pharma industry advocates that governments of all countries should focus on constantly promoting open trade, as well as on strengthening and diversifying supply chains. The experience of designing COVID-19 drugs and vaccines has shown that the processes of drug development and commercialization can be significantly expedited without compromising safety. Today, the focus is shifting to recovery in the COVID 19 aftermath, and to strengthening the ability of the healthcare system to withstand future challenges. The pharma industry will naturally be at the forefront of these efforts. What lessons can the pharmaceutical market learn from the pandemic and lockdowns, and how is the pharma industry adapting to the global healthcare transformation? Was the revision of existing industry growth programmes sufficiently thorough, and what development priorities are coming to the fore? How did the economics of the global pharmaceutical market change under the pandemic? Will the pandemic affect the industry’s attractiveness to investors, both in Russia and across the globe? Will there be an intra-industry redirection of investment flows? How well did the drug supply system in Russia function during the pandemic, given the global context? What role might innovative pharma players have in ensuring that the key needs of the healthcare system are met in the new reality?

Moderator
Dmitry Khalilov, Partner, Life Sciences & Health Leader, Central, Eastern and Southeastern Europe & Central Asia, EY

Dmitry Khalilov

Partner, Life Sciences & Health Leader, Central, Eastern and Southeastern Europe & Central Asia, EY

Over 20 years of experience in providing tax advisory services to pharmaceutical and health companies; experience in managing advisory engagements for international and Russian companies in the areas of Russian and international tax planning and tax optimization, structuring of operations, cross-border and domestic transactions and other ongoing tax issues, as well as launching an IPO on international financial markets; major clients include Takeda (Nycomed), Novo Nordisk, Abbott Laboratories, Astellas Pharma, AstraZeneca, Berlin-Chemie/Menarini, Teva, Johnson & Johnson, Pfizer, UCB, Merck, Pharmstandard, Novartis.Member of an organizational committee of the interactive discussion platform Viable Healthcare, established by The Russian Presidential Academy of National Economy and Public Administration (RANEPA) and The Business Administration of the President of the Russian Federation.
Moscow State Academy of Law, degree in Tax Law; Moscow institute of State and Corporate Management, Bachelor’s degree in Economics

Panellists
Sergey Glagolev, Deputy Minister of Health of the Russian Federation
Vitaly Dembrovsky, Director of Corporate Affairs for Healthcare and Public Health, Russia and Eurasia, AstraZeneca
Vadim Kukava, Executive Director, The Association of Pharmaceutical Companies «Innovative Pharma»
Alexey Repik, Chairman, Delovaya Rossiya (Business Russia); Chairman of the Board, Group R-Pharm
Alla Samoylova, Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)
Vladimir Shipkov, Executive Director, Association of International Pharmaceutical Manufacturers (AIPM)
Lyudmila Scherbakova, President, Bright Way Group

Vitaly Dembrovsky

Director of Corporate Affairs for Healthcare and Public Health, Russia and Eurasia, AstraZeneca

Vadim Kukava

Executive Director, The Association of Pharmaceutical Companies «Innovative Pharma»

In 2012, Vadim Kukava was offered the position of Executive Director of the Association of leading global innovative pharmaceutical companies, InPharma. During this time, the Association has become a key player in the Russian pharmaceutical market, collaborating with government bodies to develop balanced regulations of the industry for the benefit of Russian patents.
From 2006 to 2012, Vadim worked in leading international companies that produce consumer goods, in positions connected to public/GR relations and policy affairs. During this time, Vadim participated in discussions on key legislation in the sphere of regulating the tobacco and medical industries, collaborated with representatives of the Russian and European scientific communities, and played an active role in the work of industrial associations, including on the Board. In addition, Vadim was responsible for creating and developing a division for public and regulatory affairs.
From 2004 to 2006, he worked as a consultant at the Federal Agency for State Property Administration (Rosimuschestvo). Vadim was responsible for implementing the full range of powers of ownership related to property within the forestry and chemical industry owned by the Russian Federation.
In 2003, he graduated from the Faculty of Law of the International University in Moscow.

Alexey Repik

Chairman, Delovaya Rossiya (Business Russia); Chairman of the Board, Group R-Pharm

Born in Moscow, Russia on 27 August 1979.Graduated from the State University “Higher School of Economics”, Diploma in Economy and Business Administration.Since 1995 in Healthcare and Pharmaceutics.R-Pharm Founder. President of All-Russia Business Association “Delovaya Rossiya” (“Business Russia”), actively participating in the improvement of investment climate in the Russian Federation and the establishment of the regional investment standard.Member of the Economic Council under the President of the Russian Federation.Member of the Presidential Council for Priority National Projects and Demographic Policy.Member of the Expert Council under the Government of the Russian Federation. Member of the Public Chamber of the Russian Federation, Head of Commission on Investment Climate.Representative (public ombudsman) of the Commissioner of the Presidential Council on the protection of the rights of entrepreneurs on issues related to the protection of the rights of foreign investors.Board-member and Co-chairman of Committee of the Russian Union of Industrialists and Entrepreneurs on pharmaceutical and medical industry.Co-Chairman of the National Rating CommitteeMember of the Public Council under the Ministry of Industry and Trade of the Russian Federation (pharmaceutical, medical equipment and technologies).Member of the Supervisory Board of the Autonomous Nonprofit Organization "Agency for Strategic Initiatives".

Alla Samoylova

Head, Federal Service for Surveillance in Healthcare (Roszdravnadzor)

Born in Cheboksary.
1990: Graduated from the Chuvash State University named after I. N. Ulyanov with a degree in medicine.
2002: Awarded with the badge “Excellent Worker of Public Health”.
2007: Honored doctor of the Chuvash Republic.
2010: Doctor of Science in medicine.
2012: Professor of obstetrics and gynecology.
1987-1990 – nurse, obstetrician-gynecologist at the industrial hospitals in Cheboksary.
1990-1993 – Full-time postgraduate study at Chuvash State University.
1993-1994 - Assistant at the Obstetrics and Gynecology Department of the Chuvash State University.
1994-2012 – Chief Doctor of the Presidential Perinatal Center of the Ministry of Health and social development of the Chuvash Republic.
2010-2017 – Head of the Department of Obstetrics and Gynecology named after G. M. Vorontsova, of the Chuvash State University.
2012-2015 – Deputy Chair at the Cabinet of Ministers of the Chuvash Republic - Minister of Health and Social Development of the Chuvash Republic.
2015-2017 – Minister of Health of the Chuvash Republic.
2018-2019 – Adviser to the Head of the Federal Service for Surveillance in Healthcare.
2019-2020 – Head of the Department of State Control of Implementation of State Healthcare Programs, the Federal Service for Surveillance in Healthcare.
2020 – Director of the Project Activities Department, the Ministry of Health of the Russian Federation.
Since April 10, 2020 - Head of the Federal Service for Surveillance in Healthcare.

Vladimir Shipkov

Executive Director, Association of International Pharmaceutical Manufacturers (AIPM)

Education:
1974 г. – Military Institute of Foreign Languages
1991 г. – Russian State Humanities University
Professional activity
For a long time Mr. Shipkov has worked in the different governmental institutions. He has a deep knowledge and understanding of governmental functioning, as well as a wide range of contacts that contribute to the execution of the assigned duties in AIPM. His career of the government em-ployee includes, among other, the functions of the Director of Pharmaceutical Inspection of the Ministry of Healthcare of the Russian Federation, Deputy Director of the Federal Service of Intel-lectual Property, Patents and Trademarks (Russian Agency for Patents and Trademarks). Mr. Ship-kov also has working experience in the State Duma of the Russian Federation, State Customs Committee of the Russian Federation, banking sector. He served on actual military service.
Since 2007 he is heading of the Association of International Pharmaceutical Manufacturers.

Lyudmila Scherbakova

President, Bright Way Group

Front row participant
Kamil Saytkulov, Head of Communications and Government Affairs, GSK Russia